<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04585607</url>
  </required_header>
  <id_info>
    <org_study_id>3-2020-0337</org_study_id>
    <nct_id>NCT04585607</nct_id>
  </id_info>
  <brief_title>Potential Benefits of Expanded Hemodialysis in Prevention of Sarcopenia</brief_title>
  <official_title>Long-term Effects of Expanded Hemodialysis in Reduction of Large Middle Molecules in Chronic Hemodialysis Patients: Potential Benefits to the Prevention of Sarcopenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gangnam Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gangnam Severance Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study will investigate whether long term implementation of expanded hemodialysis&#xD;
      (HDx) will effectively decrease serum levels of large uremic toxins and ameliorate&#xD;
      progression of sarcopenia in patients with chronic kidney disease requiring hemodialysis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, prospective, 1:1 randomized, parallel-group, study to evaluate the&#xD;
      efficacy of expanded hemodialysis (HDx) compared to conventional hemodialysis in patients&#xD;
      with chronic kidney disease in South Korea for up to 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 19, 2020</start_date>
  <completion_date type="Anticipated">September 23, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 23, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The participant hospital currently has around 90 maintenance HD patients and it is possible to recruit 74 patients for this study. Study subjects will be randomized to each treatment arm using a random number table. As outlined in the proposal, it is estimated that we may experience up to 30% of drop out during the study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biomarkers of sarcopenia</measure>
    <time_frame>Changes in serum level of Myostatin and IGF-1 every 6 months</time_frame>
    <description>Change in blood levels of myostatin and insulin-like growth factor-1 (IGF-1)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Chronic Kidney Disease Requiring Chronic Dialysis</condition>
  <arm_group>
    <arm_group_label>Expanded hemodialysis (HDx)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HDx therapies be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required. General rules will be applied regarding dialysis prescription</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional hemodialysis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional hemodialysis therapies be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required. General rules will be applied regarding dialysis prescription</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>A medium cut-off dialyzer (Theranova) will be used for HDx.</intervention_name>
    <description>A medium cut-off dialyzer used for HDx (Theranova) must be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required. General rules will be applied regarding dialysis prescription.&#xD;
HD with MCO dialyzer (Theranova 400Â®, Baxter) vs. high-flux dialyzer (eg. Polyflux H, Baxter)</description>
    <arm_group_label>Expanded hemodialysis (HDx)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>A synthetic high-flux dialyzer (Polyflux)</intervention_name>
    <description>A synthetic high-flux dialyzer (Polyflux) used for hemodialysis must be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required.</description>
    <arm_group_label>Conventional hemodialysis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  On HD treatment over 6 months before study enrollment&#xD;
&#xD;
          -  Aged over 18 years&#xD;
&#xD;
          -  Able to give informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hemiplegia or paraplegia state&#xD;
&#xD;
          2. Planned renal transplant or conversion to peritoneal dialysis within study period&#xD;
&#xD;
          3. Active chronic infection or inflammatory conditions including autoimmune disease,&#xD;
             inflammatory arthritis and active malignancy&#xD;
&#xD;
          4. History of monoclonal gammopathy&#xD;
&#xD;
          5. Life expectancy &lt;12 months&#xD;
&#xD;
          6. Pregnancy or breast feeding&#xD;
&#xD;
          7. Receiving immunosuppressant medication&#xD;
&#xD;
          8. Inability to complete study assessments&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hyeongcheon Park</last_name>
    <phone>82-2-2019-4601</phone>
    <email>AMP97@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyeongcheon Park</last_name>
      <phone>82-2-2019-4601</phone>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 28, 2020</study_first_submitted>
  <study_first_submitted_qc>October 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2020</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gangnam Severance Hospital</investigator_affiliation>
    <investigator_full_name>Hyeongcheon Park</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcopenia</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

